FrancophonIA/ELRC3.0 huggingface dataset:
English: Raligize was to be used to treat women with cervical cancer whose disease had not responded to, or had come back after, initial treatment.
Slovenian: Zdravilo Raligize naj bi se uporabljalo za zdravljenje žensk z rakom materničnega vratu, pri katerih se bolezen ni odzvala na začetno zdravljenje ali se je ponovila.
English: What was Raligize expected to be used for?
Slovenian: Za kaj naj bi se zdravilo Raligize uporabljalo?
English: The bacteria in Raligize have had a gene inserted in their DNA so they can produce a new substance containing one of the HPV proteins, E7, linked to part of another protein, listeriolysin O. The linked protein is able to stimulate the immune system against E7.
Slovenian: Bakterijam v zdravilu Raligize so v njihovo DNK vstavili gen, tako da lahko proizvajajo novo snov, ki vsebuje eno od beljakovin virusa HPV, E7, povezano z delom druge beljakovine, listeriolizina O. Povezana beljakovina lahko spodbudi delovanje imunskega sistema proti E7.
English: How does Raligize work?
Slovenian: Kako zdravilo Raligize deluje?
English: The active substance in Raligize, axalimogene filolisbac, consists of a bacterium, Listeria monocytogenes, that has been modified so it can produce a protein that stimulates the immune (defence) system to attack cancer cells.
Slovenian: Učinkovina v zdravilu Raligize, aksalimogen filolisbak, vsebuje bakterijo Listeria monocytogenes, ki je bila spremenjena tako, da proizvaja beljakovino, ki imunski (obrambni) sistem spodbuja k napadu na rakave celice.
English: When Raligize is given to the patient, the bacteria are taken up by cells of the immune system where they stimulate it to recognize the E7 protein and attack and kill cancer cells that contain it.
Slovenian: Ko bolnica prejme zdravilo Raligize, bakterije vstopijo v celice imunskega sistema in ga spodbudijo k prepoznavi beljakovine E7 ter k napadu in uničenju rakavih celic, ki vsebujejo to beljakovino.
English: Cervical cancer is mainly caused by long-lasting infection with certain strains of the human papillomavirus (HPV), which produce proteins in infected cells that stimulate them to grow and become cancerous.
Slovenian: Rak materničnega vratu je večinoma posledica dolgotrajne okužbe z določenimi sevi humanega papilomavirusa (HPV).
English: * Tissue culture infectious dose 50%
Slovenian: * 50% infektivnega odmerka za tkivno kulturo
English: --1 Lyophilisate (live attenuated) Canine distemper virus, strain Bio CDV 11/A
Slovenian: --1 Liofilizat (živi atenuirani) Virus pasje kuge, sev CDV Bio 11/A
English: Canine parvovirus Type 2b, strain CPV-2b Bio 12/B
Slovenian: Virus pasjega parvovirusa tipa 2b, sev CPV-2b Bio 12/B 104,3 -106,6 TCID50* Virus pasje parainfluence tipa 2, sev CPiV-2 Bio 15
English: moroctocog alfa
Slovenian: moroktokog alfa
English: The European Commission granted a marketing authorisation valid throughout the European Union for ReFacto AF on 13 April 1999.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom ReFacto AF, veljavno po vsej Evropski uniji, izdala 13. aprila 1999.
English: The full EPAR for ReFacto AF can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo ReFacto AF je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What measures are being taken to ensure the safe and effective use of ReFacto AF?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila ReFacto AF?
English: Therefore, the Committee decided that the benefits of ReFacto AF are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: Odbor je zato zaključil, da so koristi zdravila ReFacto AF večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
English: Following these changes, the company carried out a study to show that ReFacto and ReFacto AF were treated by the body in the same way.
Slovenian: Po teh spremembah je družba izvedla študijo, da bi dokazala, da se telo na zdravili ReFacto in ReFacto AF odziva enako.
English: These are known as inhibitors as they can prevent the medicine from working effectively, which may result in a loss of bleeding control.
Slovenian: Ta so znana kot zaviralci, saj lahko preprečijo učinkovito delovanje zdravila, kar ima lahko za posledico izgubo nadzora nad krvavitvijo.
English: What benefit has ReFacto AF shown during the studies?
Slovenian: Kakšne koristi je zdravilo ReFacto AF izkazalo med študijami?
English: It also carried out two main studies looking at the effectiveness of ReFacto AF: the first looked at the prevention and treatment of bleeding episodes in 94 previously treated patients and the second looked at the prevention of bleeding in 22 patients having surgery.
Slovenian: Izvedla je tudi dve glavni študiji, v katerih je proučila učinkovitost zdravila ReFacto AF: v prvi študiji so raziskovali preprečevanje in zdravljenje epizod krvavenja pri 94 predhodno zdravljenih bolnikih, v drugi pa preprečevanje krvavenja pri 22 bolnikih po operativnem posegu.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Refacto AF have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo zdravstveni delavci in bolniki upoštevati za varno in učinkovito uporabo zdravila ReFacto AF, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Patients or their carers can give injections of ReFacto AF, provided that they have been trained appropriately.
Slovenian: Bolniki ali njihovi negovalci lahko zdravilo ReFacto AF injicirajo sami, če so bili za to ustrezno usposobljeni.
English: The human coagulation factor VIII in ReFacto AF is not extracted from human blood but is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to produce human coagulation factor VIII.
Slovenian: Humani koagulacijski faktor VIII v zdravilu ReFacto AF se ne pridobiva iz človeške krvi, temveč se proizvaja z metodo, znano kot “tehnologija rekombinantne DNK”, pri kateri celica prejme gen (DNK), s katerim lahko tvori humani koagulacijski faktor VIII.
English: For more information about treatment with ReFacto AF, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom ReFacto AF preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: The dose and the frequency of treatment depend on whether ReFacto AF is used to treat or prevent bleeding, the seriousness of the condition, the extent and location of the bleeding or the type of surgery, and the patient's bodyweight.
Slovenian: Odmerek in pogostnost odmerjanja sta odvisna od tega, ali se zdravilo ReFacto AF uporablja za zdravljenje ali preprečevanje krvavitve, od resnosti stanja, mesta in obsežnosti krvavitve ali vrste operativnega posega ter bolnikove telesne mase.
English: Other information about ReFacto AF
Slovenian: Druge informacije o zdravilu ReFacto AF
English: The CHMP noted that ReFacto AF was comparable to ReFacto, the original form of the medicine.
Slovenian: CHMP je ugotovil, da je zdravilo ReFacto AF primerljivo z prvotno obliko zdravila, tj. zdravilom ReFacto.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for ReFacto AF.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo ReFacto AF, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: The active substance in ReFacto AF, moroctocog alfa, works in the body in the same way as human factor VIII.
Slovenian: Zdravilna učinkovina v zdravilu ReFacto AF, moroktokog alfa, deluje v telesu enako kot humani faktor VIII.
English: In February 2009, a number of changes to the way ReFacto is made were introduced.
Slovenian: Februarja 2009 se je način izdelave zdravila ReFacto bistveno spremenil.
English: This is a summary of the European public assessment report (EPAR) for ReFacto AF.
Slovenian: Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo ReFacto AF.
English: ReFacto AF was first authorised as ReFacto in April 1999, for use in previously treated and untreated patients with haemophilia A, based on the results of three main studies.
Slovenian: Zdravilo ReFacto AF je bilo najprej odobreno aprila 1999 kot zdravilo ReFacto za uporabo pri bolnikih s predhodno zdravljeno ali nezdravljeno hemofilijo A na podlagi rezultatov treh glavnih študij.
English: Full details on how to calculate the dose are included in the summary of product characteristics (also part of the EPAR).
Slovenian: Podrobnejši podatki o izračunavanju ustreznega odmerka so na voljo v povzetku glavnih značilnosti zdravila (ki je prav tako del EPAR).
English: Uncommonly, patients may also develop allergic reactions.
Slovenian: Redko so lahko pri bolnikih izzvane alergijske reakcije.
English: The most common side effects with ReFacto AF (seen in more than 1 patient in 10) are headache, cough, pain in the joints and fever.
Slovenian: Najpogostejši neželeni učinki zdravila ReFacto AF (opaženi pri več kot 1 bolniku od 10) so glavobol, kašelj, bolečine v sklepih in povišana telesna temperature.
English: ReFacto AF can be used in patients of all ages, including newborns.
Slovenian: Zdravilo ReFacto AF je primerno za uporabo pri bolnikih vseh starosti, vključno z novorojenčki.
English: Patients may also develop antibodies against factor VIII medicines such as Refacto AF.
Slovenian: Bolniki lahko pri zdravilih, kot je ReFacto AF razvijejo protitelesa faktorja VIII.
English: Patients with haemophilia A lack factor VIII, a protein needed for normal clotting of the blood, and as a result, they bleed readily and may have problems, such as bleeding in the joints, muscles and internal organs.
Slovenian: Bolnikom s hemofilijo A primanjkuje faktorja VIII, tj. beljakovine, ki je potrebna za normalno strjevanje krvi, zato hitreje zakrvavijo in imajo lahko težave, kot so krvavitve v sklepih, mišicah in notranjih organih.
English: These included removal of the use of a protein called albumin, which is produced from human blood, from the manufacturing process.
Slovenian: Med drugim se je v proizvodnem procesu prenehala uporabljati beljakovina, imenovana albumin, ki se pridobiva iz človeške krvi.
English: ReFacto AF is given by injection into a vein over several minutes.
Slovenian: Zdravilo ReFacto AF se z injekcijo dovaja v veno več minut.
English: ReFacto AF must not be used in people who are hypersensitive (allergic) to human coagulation factor VIII, to any of the other ingredients or to hamster proteins.
Slovenian: Zdravila ReFacto AF ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) humani koagulacijski faktor VIII, za katero koli drugo sestavino zdravila ali za beljakovine hrčka.
English: The name of the medicine was also changed from ReFacto to ReFacto AF.
Slovenian: Spremenjeno je bilo tudi ime zdravila, iz ReFacto v ReFacto AF.
English: ReFacto AF should be started under the supervision of a doctor who has experience in the treatment of haemophilia A.
Slovenian: Zdravljenje z zdravilom ReFacto AF mora uvesti zdravnik, ki ima izkušnje z zdravljenjem hemofilije A.
English: It is available as vials or pre-filled syringes.
Slovenian: Na voljo je v vialah ali predhodno napolnjenih injekcijskih brizgah.
English: ReFacto AF is used for the treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder).
Slovenian: Zdravilo ReFacto AF se uporablja za zdravljenje in preprečevanje krvavitev pri bolnikih s hemofilijo A (prirojeno motnjo strjevanja krvi).
English: For the full list of all side effects reported with ReFacto AF, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila ReFacto AF, glejte navodilo za uporabo.
English: Why has ReFacto AF been approved?
Slovenian: Zakaj je bilo zdravilo ReFacto AF odobreno?
English: ReFacto AF contains the active substance moroctocog alfa.
Slovenian: Zdravilo ReFacto AF vsebuje zdravilno učinkovino moroktokog alfa.
English: What is the risk associated with ReFacto AF?
Slovenian: Kakšna tveganja so povezana z zdravilom ReFacto AF?
English: How has ReFacto AF been studied?
Slovenian: Kako je bilo zdravilo ReFacto AF raziskano?
English: The studies showed that ReFacto AF was as safe and effective as ReFacto in preventing and treating bleeding episodes in patients with haemophilia A.
Slovenian: Študije so pokazale, da je zdravilo ReFacto AF pri preprečevanju in zdravljenju epizod krvavitev pri bolnikih s hemofilijo A enako varno in učinkovito kot zdravilo ReFacto.
English: ReFacto AF is a powder and solvent used to make up a solution for injection.
Slovenian: Zdravilo ReFacto AF sestavljata prašek in vehikel, ki se zmešata v raztopino za injiciranje.
English: What is ReFacto AF used for?
Slovenian: Za kaj se zdravilo ReFacto AF uporablja?
English: How is ReFacto AF used?
Slovenian: Kako se zdravilo ReFacto AF uporablja?
English: What is ReFacto AF?
Slovenian: Kaj je zdravilo ReFacto AF?
English: MA (EU) Number
Slovenian: Št. dovoljenja za promet (EU)
English: (Invented) name Strength Pharmaceutical Form
Slovenian: (Lastniško) ime Jakost
English: However it should be noted that patients in this study were given doses higher than the recommended dose (up to 10 mg twice a day).
Slovenian: Vendar je treba omeniti, da so bolniki v tej študiji prejemali večje odmerke od priporočenega odmerka (do 10 mg dvakrat na dan).
English: Side effects reported with this medicine are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri tem zdravilu, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: It must not be used in women who are pregnant, breastfeeding or by women who could become pregnant and who are not using appropriate contraceptives.
Slovenian: Ne smejo ga uporabljati nosečnice, doječe matere ali ženske, ki bi lahko zanosile in ki ne uporabljajo ustreznih kontracepcijskih sredstev.
English: This authorisation was based on the authorisation granted to Procoralan in 2005 (‘informed consent').
Slovenian: Izdaja tega dovoljenja je temeljila na dovoljenju za promet z zdravilom Procoralan, ki je bilo izdano leta 2005 (uporaba dokumentacije s soglasjem).
English: Further information on Ivabradine Anpharm can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Ivabradine-Anpharm.
Slovenian: Več informacij o zdravilu Ivabradine Anpharm je na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Ivabradine-Anpharm.
English: When used for angina, treatment should be stopped if symptoms do not improve after 3 months.
Slovenian: Kadar se uporablja za zdravljenje angine pektoris, je treba zdravljenje prekiniti, če se simptomi po treh mesecih ne izboljšajo.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ivabradine Anpharm have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Ivabradine Anpharm upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Ivabradine Anpharm is available as tablets (5 and 7.5 mg) and can only be obtained with a prescription.
Slovenian: Zdravilo Ivabradine Anpharm je na voljo v obliki tablet (5 in 7,5 mg), predpisovanje in izdaja pa je le na recept.
English: Ivabradine Anpharm must not be taken with a number of other medicines.
Slovenian: Zdravilo Ivabradine Anpharm se ne sme jemati skupaj s številnimi drugimi zdravili.
English: However, a fifth study in 728 patients showed that adding Ivabradine Anpharm to amlodipine did not provide an additional benefit.
Slovenian: V peti študiji s 728 bolniki pa so dokazali, da dodajanje zdravila Ivabradine Anpharm amlodipinu ne prinaša dodatnih koristi.
English: Ivabradine Anpharm received a marketing authorisation valid throughout the EU on 8 September 2015.
Slovenian: Za zdravilo Ivabradine Anpharm je bilo 8. septembra 2015 izdano dovoljenje za promet, veljavno po vsej EU.
English: Results showed that it was more effective than placebo at preventing death due to disease of the heart or blood vessels or hospitalisation due to worsening heart failure: 24.5% (793 out of 3,241) of patients treated with Ivabradine Anpharm died or were hospitalised due to worsening heart failure, compared with 28.7% (937 out of 3,264) of patients receiving placebo.
Slovenian: Rezultati so pokazali, da je bilo to zdravilo učinkovitejše od placeba pri preprečevanju smrti zaradi bolezni srca ali ožilja ali hospitalizacije zaradi poslabšanja srčnega popuščanja: 24,5 % (793 od 3 241) bolnikov, zdravljenih z zdravilom Ivabradine Anpharm, je umrlo ali je bilo hospitaliziranih zaradi poslabšanja srčnega popuščanja v primerjavi z 28,7 % (937 od 3 264) bolnikov, ki so prejemali placebo.
English: What measures are being taken to ensure the safe and effective use of Ivabradine Anpharm?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ivabradine Anpharm?
English: Ivabradine Anpharm (ivabradine)
Slovenian: Ivabradine Anpharm (ivabradin)
English: The Agency decided that Ivabradine Anpharm's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Zato je zaključila, da so koristi zdravila Ivabradine Anpharm večje od z njim povezanih tveganj, in da se lahko odobri za uporabo v EU.
English: In a fourth study in 889 patients, Ivabradine Anpharm was more effective than placebo when both were added to atenolol.
Slovenian: V četrti študiji z 889 bolniki je bilo zdravilo Ivabradine Anpharm učinkovitejše od placeba, pri čemer so oba dodajali atenololu.
English: Ivabradine Anpharm therefore reduces or prevents the symptoms of angina.
Slovenian: Zdravilo Ivabradine Anpharm tako zmanjša ali prepreči simptome angine pektoris.
English: As for all medicines, data on the use of Ivabradine Anpharm are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Ivabradine Anpharm stalno spremljajo.
English: Ivabradine Anpharm must not be used in patients who have a resting heart rate below 70 beats per minute, very low blood pressure, various types of heart disorder (including cardiogenic shock, rhythm disorders, heart attack, unstable or acute (sudden) heart failure and unstable angina) or severe liver problems.
Slovenian: Zdravila Ivabradine Anpharm ne smejo jemati bolniki, ki imajo srčni utrip med mirovanjem nižji od 70 udarcev na minuto, zelo nizek krvni tlak, razne vrste obolenj srca (npr. kardiogeni šok, motnje ritma, srčni napad, nestabilno ali akutno (nenadno) srčno popuščanje in nestabilno angino pektoris) ali hude težave z jetri.
English: The most common side effect with Ivabradine Anpharm (which may affect more than 1 in 10 people) is luminous phenomena or ‘phosphenes' (a temporary brightness in the field of vision).
Slovenian: Najpogostejši neželeni učinek zdravila Ivabradine Anpharm (ki se lahko pojavi pri več kot 1 bolniku od 10) so pojav svetlikanja ali „fosfeni“ (prehodno povečanje svetlosti v vidnem polju).
English: For more information about using Ivabradine Anpharm, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Ivabradine Anpharm glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: The European Medicines Agency concluded that Ivabradine Anpharm was shown to be effective in longterm angina with an acceptable safety profile for it to provide an alternative treatment for patients who cannot take beta blockers or whose disease is not controlled with them.
Slovenian: Evropska agencija za zdravila je zaključila, da je bilo za zdravilo Ivabradine Anpharm dokazano, da je učinkovito pri zdravljenju kronične angine pektoris in ima zadosten varnostni profil za nadomestno zdravljenje bolnikov, ki ne morejo jemati zaviralcev receptorjev beta oziroma katerih bolezen ni urejena z njimi.
English: An overview of Ivabradine Anpharm and why it is authorised in the EU
Slovenian: Pregled zdravila Ivabradine Anpharm in zakaj je odobreno v EU
English: In this study, a specific subgroup of patients who had symptomatic angina had a small but significant increase in the combined risk of cardiovascular death or non-fatal heart attack with Ivabradine Anpharm compared with placebo (3.4% vs 2.9% yearly incidence rates).
Slovenian: V tej študiji je pri posebni podskupini bolnikov s simptomatsko angino pektoris, zdravljenih z zdravilom Ivabradine Anpharm, prišlo do majhnega, vendar pomembnega povečanja združenega tveganja smrti zaradi srčno-žilne bolezni ali srčnega napada brez smrtnega izida v primerjavi s placebom (letni delež pogostnosti 3,4 % v primerjavi z 2,9 %).
English: The medicine is used in patients who have a normal heart rhythm and whose heart rate is at least 70 beats per minute.
Slovenian: Zdravilo se uporablja pri bolnikih z normalnim srčnim ritmom, ki ne sme biti manjši od 70 utripov na minuto.
English: Ivabradine Anpharm is a heart medicine used to treat the symptoms of long-term stable angina (pains to the chest, jaw and back, brought on by physical effort) in adults with coronary artery disease (disease of the heart caused by the obstruction of the blood vessels that supply blood to the heart muscle).
Slovenian: Ivabradine Anpharm je zdravilo za srce, ki se uporablja za zdravljenje simptomov kronične stabilne angine pektoris (bolečine v prsnem košu, čeljusti in hrbtu zaradi telesnega napora) pri odraslih z boleznijo koronarnih arterij (boleznijo srca, ki jo povzroča zamašitev krvnih žil, ki dovajajo kri v srčno mišico).
English: A sixth study compared Ivabradine Anpharm with placebo in 19,102 patients with coronary artery disease and without clinical heart failure.
Slovenian: V šesti študiji so zdravilo Ivabradine Anpharm primerjali s placebom pri 19 102 bolnikih z boleznijo koronarnih arterij brez kliničnega srčnega popuščanja.
English: It was as effective as atenolol (a beta blocker) in a study of 939 patients and as effective as amlodipine (another medicine used to treat angina) in a study of 1,195 patients.
Slovenian: V študiji z 939 bolniki je bilo enako učinkovito kot atenolol (zaviralec receptorjev beta), v študiji s 1 195 bolniki pa enako učinkovito kot amlodipin (drugo zdravilo, ki se uporablja za zdravljenje angine pektoris).
English: Ivabradine Anpharm is also used in patients with long-term heart failure (when the heart cannot pump enough blood to the rest of the body) who have a normal heart rhythm and whose heart rate is at least 75 beats per minute.
Slovenian: Zdravilo Ivabradine Anpharm se uporablja tudi pri bolnikih s kroničnim srčnim popuščanjem (kadar srce ne more črpati dovolj krvi po telesu), ki imajo sicer normalen srčni ritem, a je njihov srčni utrip najmanj 75 udarcev na minuto.
English: Why is Ivabradine Anpharm authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Ivabradine Anpharm odobreno v EU?
English: Other information about Ivabradine Anpharm
Slovenian: Druge informacije o zdravilu Ivabradine Anpharm
English: What is Ivabradine Anpharm and what is it used for?
Slovenian: Kaj je zdravilo Ivabradine Anpharm in za kaj se uporablja?
English: What benefits of Ivabradine Anpharm have been shown in studies?
Slovenian: Kakšne koristi zdravila Ivabradine Anpharm so se pokazale v študijah?